FIG 5.

Hepatic Map4k4 does not contribute to systemic glucose tolerance or insulin responsiveness. (A) Schematic of alleles and transgenes used to inactivate Map4k4 using albumin-cre transgene. (B) Relative levels of Map4k4 mRNA expression in liver, skeletal muscle, and adipose tissue (n = 7 to 14). (C) Relative levels of Map4k4 mRNA expression in isolated hepatocytes (n = 3). (D to M) Mice were fed an ND or an HFD for 16 weeks. (D) Body weight (n = 6 to 13). (E) Liver weight (n = 6 to 17). (F) Fasting insulin levels (n = 4 to 15). (G) NEFA levels of HFD-fed mice (n = 4 to 15). (H) GTT (n = 8 to 16). (I) ITT (n = 8 to 16). (J) Blood glucose levels during pyruvate tolerance test (PTT) (n = 7 to 16). (K) Livers were isolated and RT-qPCR performed on the indicated genes of HFD-fed animals (n = 5 to 7). (L) Representative liver histology of HFD-fed mice. Slides were stained with H&E (n = 10). (M) Liver triglyceride (TG) extraction from HFD-fed mice (n = 5 to 11). Results are means ± SEM (*, P < 0.01; ***, P < 0.0001).